Literature DB >> 7575530

The protein kinase C activator Bryostatin-1 induces the rapid release of TNF alpha from MONO-MAC-6 cells.

K G Steube1, H G Drexler.   

Abstract

Bryostatin-1 is a natural activator of protein kinase C and currently examined in phase I trials as anticancer agent. We found that Bryostatin-1 induced tumor necrosis factor alpha (TNF alpha) expression in the human cell line MONO-MAC-6. Using Northern blot analysis and a bioassay for the detection of the cytokine we observed that Bryo alone was sufficient to transiently induce mRNA synthesis and the rapid release of TNF alpha into the culture medium. However, the combination of Bryo with lipopolysaccharide resulted in a strong synergistic increase of TNF alpha secretion. The biologic activity of the secreted TNF alpha was amenable to inhibition by anti-TNF alpha antibodies. Blockade of the lipopolysaccharide receptor CD14 or inhibition of protein kinase C implied that both, CD14 and protein kinase C, are involved individually in signal transduction pathways leading to TNF alpha secretion from MONO-MAC-6 cells. The results demonstrate that Bryostatin-1 is able to induce TNF alpha secretion in human monocytes via a protein kinase C-dependent and CD14-independent pathway and by a mechanism which is most likely based on a strong increase of the TNF alpha mRNA level.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575530     DOI: 10.1006/bbrc.1995.2413

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Molecular Events as Targets of Anticancer Drug Therapy.

Authors:  Adorján Aszalós; Sándor Eckhardt
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

2.  Modulation of lipopolysaccharide-induced monocyte activation by heparin-binding protein and fucoidan.

Authors:  M Heinzelmann; H C Polk; F N Miller
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

3.  Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors.

Authors:  S F Thijsen; G J Schuurhuis; J W van Oostveen; A P Theijsmeijer; K G van der Hem; J H Odding; A M Dräger; G J Ossenkoppele
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

4.  A phase II study of bryostatin 1 in metastatic malignant melanoma.

Authors:  D J Propper; V Macaulay; K J O'Byrne; J P Braybrooke; S M Wilner; T S Ganesan; D C Talbot; A L Harris
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.